The robust Phase 2b data and FDA clearance de-risk the path to Phase 3, making GHRS a compelling speculative long ahead of FDA alignment discussions. Monitor for official Phase 3 initiation timeline and any updates on the proprietary aerosol device development. The strong cash position supports at least 2–3 years of operations without immediate dilution risk.
Price Chart
Executive Summary
GH Research reported financial results for 2025, highlighted by a strong Phase 2b trial for GH001 in treatment-resistant depression (TRD), meeting its primary endpoint with a placebo-adjusted MADRS reduction of -15.5 points (p<0.0001). The company ended the year with $280.7 million in cash, up from $182.6 million in 2024, despite a wider net loss of $48.3 million. It is now seeking FDA alignment on a global Phase 3 program to replicate these results, with trial initiation targeted for 2026.
Key Financial Metrics
Key Facts
- Phase 2b trial of GH001 in TRD met primary endpoint: -15.5 MADRS reduction vs placebo at Day 8 (p<0.0001)
- 57.5% remission rate (MADRS ≤10) on GH001 at Day 8 vs 0% on placebo
- 73% remission rate at 6 months in open-label extension with infrequent retreatment
- No treatment-related serious adverse events or suicidal behavior observed
- Cash, cash equivalents, and marketable securities: $280.7 million as of Dec 31, 2025, up from $182.6 million in 2024
- Net loss widened to $48.3 million ($0.79/share) from $39.0 million ($0.75/share) in 2024
- R&D expenses increased to $38.8M from $35.0M; G&A rose to $22.0M from $15.3M
- FDA cleared GH001 for U.S. clinical investigation, enabling U.S. enrollment
Financial Impact
Cash position increased by $98.1 million year-over-year despite higher operating losses, indicating strong capital efficiency and funding runway. Net loss increased 24% YoY, driven by higher R&D and G&A, but remains manageable against cash balance.
Risk Factors
- Phase 3 trial design may differ from Phase 2b, potentially affecting outcome reproducibility
- FDA may not align on pivotal program design or could impose additional requirements
- Future capital raises could dilute shareholders, though not immediately necessary
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $19.18 (−9.14%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $19.18 (−29.49%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $19.18 (−37.40%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $19.18 (−0.10%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $19.18 (+31.64%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $19.18 (+40.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers